Fox Run Management’s Cogent Biosciences COGT Stock Holding History

Fox Run Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$738K	Buy	19,072 +13,274	+229%	+$464K	0.12%	310
2026 Q1	$205K	Buy	+5,798	New	+$214K	0.04%	760
2025 Q3	–	Sell	-26,385	Closed	-$189K	–	968
2025 Q2	$189K	Sell	26,385 -20,241	-43%	-$112K	0.03%	759
2025 Q1	$279K	Buy	46,626 +36,518	+361%	+$286K	0.04%	693
2024 Q4	$78.8K	Sell	10,108 -12,570	-55%	-$125K	0.01%	821
2024 Q3	$245K	Buy	+22,678	New	+$221K	0.05%	612
2023 Q4	–	Sell	-10,111	Closed	-$98.6K	–	761
2023 Q3	$98.6K	Buy	+10,111	New	+$120K	0.03%	625
2022 Q4	–	Sell	-18,621	Closed	-$278K	–	662
2022 Q3	$278K	Buy	+18,621	New	+$255K	0.11%	373

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fox Run Management's COGT Position: Q2 2026 in Review

Fox Run Management increased its Cogent Biosciences (COGT) stake by 229% in Q2 2026, buying an estimated $464K and bringing the position to 19,072 shares worth $738K. The position accounts for 0.12% of the portfolio, ranked #310.

Fox Run Management first reported a position in COGT in Q3 2022 and has held it in 8 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Fox Run Management held 19,072 shares of Cogent Biosciences worth $738K as of Q2 2026.
Fox Run Management bought 13,274 Cogent Biosciences shares in Q2 2026, an estimated $464K.
Cogent Biosciences made up 0.12% of Fox Run Management's portfolio in Q2 2026, its #310 holding.
Fox Run Management first reported a position in Cogent Biosciences in Q3 2022 and has held it in 8 quarters since.
322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.